Cargando…

Clinical Experience with Daptomycin for the Treatment of Gram-positive Infections in Children and Adolescents

BACKGROUND: This subgroup analysis of the European Cubicin Outcomes Registry Experience evaluated the safety and effectiveness of daptomycin in children and adolescent patients (<18 years). METHODS: Clinical outcomes at the end of therapy were assessed as success (cured or improved), failure or n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Syriopoulou, Vassiliki, Dailiana, Zoe, Dmitriy, Nisichenko, Utili, Riccardo, Pathan, Rashidkhan, Hamed, Kamal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Williams & Wilkins 2016
Materias:	Antimicrobial Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830747/ https://www.ncbi.nlm.nih.gov/pubmed/26849158 http://dx.doi.org/10.1097/INF.0000000000001076

Ejemplares similares

Daptomycin for the Treatment of Infective Endocarditis: Results from European Cubicin(®) Outcomes Registry and Experience (EU-CORE)
por: Guleri, Achyut, et al.
Publicado: (2015)

Daptomycin for Gram-positive Infections in Patients with Neutropenia: Clinical Experience from a European Outcomes Registry
por: Keil, Felix, et al.
Publicado: (2015)

Daptomycin in the Clinical Setting: 8-Year Experience with Gram-positive Bacterial Infections from the EU-CORE(SM) Registry
por: Gonzalez-Ruiz, Armando, et al.
Publicado: (2015)

Real-World Treatment of Complicated Skin and Soft Tissue Infections with Daptomycin: Results from a Large European Registry (EU-CORE)
por: Cogo, Alberto, et al.
Publicado: (2015)

Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin(®) Outcomes Registry and Experience
por: Seaton, R. Andrew, et al.
Publicado: (2015)

MCR-1-dependent lipid remodelling compromises the viability of Gram-negative bacteria
por: Feng, Siyuan, et al.
Publicado: (2022)

Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE
por: Seaton, R. Andrew, et al.
Publicado: (2016)

Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infections
por: Gonzalez-Ruiz, Armando, et al.
Publicado: (2016)

Relationship Between Real-time TDM-guided Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam Monotherapy and Microbiologic Outcome in the Treatment of Critically Ill Children With Severe Documented Gram-negative Infections
por: Gatti, Milo, et al.
Publicado: (2023)

A Phase 3, Randomized, Investigator-blinded Trial Comparing Ceftobiprole With a Standard-of-care Cephalosporin, With or Without Vancomycin, for the Treatment of Pneumonia in Pediatric Patients
por: Bosheva, Miroslava, et al.
Publicado: (2021)

Cefiderocol, a new antibiotic against multidrug-resistant Gram-negative bacteria
por: Silva, José Tiago, et al.
Publicado: (2021)

Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients
por: Rubino, Christopher M., et al.
Publicado: (2021)

Daptomycin for the Treatment of Gram-Positive Periprosthetic Hip Infections: Can Daptomycin Prevent the Implant Removal?
por: Oe, Kenichi, et al.
Publicado: (2021)

Outpatient Antibiotic Prescribing for 357,390 Children With Otitis Media
por: Csonka, Péter, et al.
Publicado: (2022)

Prevalence of multidrug-resistant coagulase-positive staphylococci in canine and feline dermatological patients over a 10-year period: a retrospective study
por: Burke, Mikaela, et al.
Publicado: (2023)

Pediatric Antifungal Prescribing Patterns Identify Significant Opportunities to Rationalize Antifungal Use in Children
por: Ferreras-Antolín, Laura, et al.
Publicado: (2021)

Treatment of gram-positive deep sternal wound infections in cardiac surgery -experiences with daptomycin-
por: Popov, Aron F, et al.
Publicado: (2011)

Brazilian experience in EU-CORE: daptomycin registry and treatment of serious Gram-positive infections
por: Timerman, Artur, et al.
Publicado: (2013)

Baloxavir Marboxil 2% Granules in Japanese Children With Influenza: An Open-label Phase 3 Study
por: Yokoyama, Takato, et al.
Publicado: (2020)

Evaluation of Ceftriaxone Plus Avibactam in an Intracellular Hollow Fiber Model of Tuberculosis: Implications for the Treatment of Disseminated and Meningeal Tuberculosis in Children
por: Srivastava, Shashikant, et al.
Publicado: (2020)

Safety and Efficacy of Baloxavir Marboxil in Influenza-infected Children 5–11 Years of Age: A Post Hoc Analysis of a Phase 3 Study
por: Baker, Jeffery B., et al.
Publicado: (2023)

Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial
por: Roilides, Emmanuel, et al.
Publicado: (2023)

Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2)
por: Baker, Jeffrey, et al.
Publicado: (2020)

Daptomycin use in patients with osteomyelitis: a preliminary report from the EU-CORE(SM) database
por: Seaton, R. Andrew, et al.
Publicado: (2013)

Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens
por: Beiras-Fernandez, Andres, et al.
Publicado: (2010)

Daptomycin for the treatment of major gram-positive infections after cardiac surgery
por: Kornberger, A., et al.
Publicado: (2016)

Daptomycin Population Pharmacokinetics in Patients Affected by Severe Gram-Positive Infections: An Update
por: Balice, Giuseppe, et al.
Publicado: (2022)

Activity of Plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece
por: Galani, Irene, et al.
Publicado: (2012)

Micafungin in Premature and Non-premature Infants: A Systematic Review of 9 Clinical Trials
por: Manzoni, Paolo, et al.
Publicado: (2014)

A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis
por: Benjamin, Daniel K., et al.
Publicado: (2018)

Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants
por: Domachowske, Joseph B., et al.
Publicado: (2018)

Antibiotic Resistance Among Pediatric-Sourced Ocular Pathogens: 8-Year Findings From the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) Surveillance Study
por: Alter, Sherman J., et al.
Publicado: (2019)

Exploiting Homoplasy in Genome-Wide Association Studies to Enhance Identification of Antibiotic-Resistance Mutations in Bacterial Genomes
por: Lai, Yi-Pin, et al.
Publicado: (2020)

A Novel Cecropin D-Derived Short Cationic Antimicrobial Peptide Exhibits Antibacterial Activity Against Wild-Type and Multidrug-Resistant Strains of Klebsiella pneumoniae and Pseudomonas aeruginosa
por: Ocampo-Ibáñez, Iván Darío, et al.
Publicado: (2020)

Draft Genome Sequence of Ciprofloxacin and Ceftriaxone Resistant Campylobacter jejuni MM26-781 Assigned to Novel ST Isolated From Common Pigeon in Lithuania
por: Aksomaitiene, Jurgita, et al.
Publicado: (2019)

Molecular Docking of Broad-Spectrum Antibodies on Hemagglutinins of Influenza A Virus
por: Le, Khanh PB, et al.
Publicado: (2019)

Simulated Comparison of a Bayesian Clinical Decision Support System Versus Standard of Care For Achieving Gentamicin Pharmacokinetic Targets in Neonates
por: Yu, Collin Z., et al.
Publicado: (2020)

Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia
por: Roilides, Emmanuel, et al.
Publicado: (2020)

Prevalence and risk analysis of mobile colistin resistance and extended-spectrum β-lactamase genes carriage in pet dogs and their owners: a population based cross-sectional study
por: Lei, Lei, et al.
Publicado: (2021)

Characterization of an NDM-5-producing hypervirulent Klebsiella pneumoniae sequence type 65 clone from a lung transplant recipient
por: Zhao, Jiankang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_13vk8fdogksoss55i0bg6mlp6q